Please Wait.....
Report
Progressive Fibrosing Interstitial Lung Disease (pfild) - Epidemiology Forecast - 2032
Market Report I 2022-08-01 I 90 Pages I DelveInsight
DelveInsight's 'Progressive Fibrosing Interstitial Lung Disease (PF-ILD)- Epidemiology Forecast-2032' report delivers an in-depth understanding of the Progressive Fibrosing Interstitial Lung Disease, historical and forecasted epidemiology as well as the PF-ILD trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Progressive Fibrosing Interstitial Lung Disease Understanding
Progressive Fibrosing Interstitial Lung Disease (PF-ILD) consists of a diverse group of interstitial lung diseases (ILDs) characterized by a similar clinical phenotype of accelerated respiratory failure, frequent disease exacerbation and earlier mortality.
Interstitial lung disease is believed to be caused by long-term exposure to hazardous materials, such as asbestos or coal dust, or it can be caused by an auto-immune disease such as rheumatoid arthritis. Once lung scarring occurs, it is generally irreversible.
Progressive Fibrosing Interstitial Lung Diseases are composed of Idiopathic Interstitial Pneumonias such as non-specific interstitial pneumonia and unclassifiable interstitial pneumonia, and inhalation lung diseases such as chronic hypersensitivity pneumonia, and connective tissue disease-associated ILD such as rheumatoid arthritis-related ILD and SSc-related ILD, and sarcoidosis and so on. Many interstitial lung diseases (ILDs) are characterized by chronic progressive fibrosis. The type-specific segmentation majorly includes, Idiopathic Interstitial Pneumonias (IIPs), Autoimmune ILDs, Hypersensitivity Pneumonitis, Sarcoidosis, and other ILDs.
Progressive Fibrosing Interstitial Lung Disease Diagnosis
Imaging tests such as X-ray and a high-resolution computed tomography (CT scan), is key to, and sometimes the first step in, the diagnosis of interstitial lung disease. The severity level of Progressive Fibrosing Interstitial Lung Disease is calculated on the basis of FVC score. However, identifying and determining the cause of interstitial lung disease can be challenging, as a large number of disorders fall into this broad category. Hence differential diagnosis is needed.
The differential diagnosis of Interstitial Lung Diseases requires a multidisciplinary approach, usually involving pulmonologist, radiologist, and pathologist. The evaluations include clinical presentation, specific history assessment, smoking status, lung function evaluation, serological test results, imaging and if required, lung biopsy.
Continued in the report..
Progressive Fibrosing Interstitial Lung Disease Epidemiology Perspective by DelveInsight
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Prevalent Cases of Interstitial Lung Disease (ILD), Total Diagnosed Prevalent Cases of Interstitial Lung Disease (ILD), Type-specific Diagnosed Prevalent Cases of Interstitial Lung Disease (ILD), Total Diagnosed Prevalent Cases of Progressive Fibrosing Interstitial Lung Disease (PF-ILD), in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan, from 2019 to 2032.
Progressive Fibrosing Interstitial Lung Disease Detailed Epidemiology Segmentation
- In the assessment done by DelveInsight, the estimated total diagnosed prevalent cases of Progressive Fibrosing Interstitial Lung Disease (PF-ILD) in the 7MM were 322,197 in 2021.
- The highest total diagnosed prevalent cases of Progressive Fibrosing Interstitial Lung Disease were accounted by the US in 2021 (166,393 cases), which are expected to show a rise in the future.
- Among the European countries, Germany had the highest diagnosed prevalent cases of PF-ILD with 31,807 cases, followed by the United Kingdom, which had prevalent population of 25,446 in 2021. On the other hand, Spain had the lowest prevalent population (17,834 cases).
- Japan had 31,542 total diagnosed prevalent cases of Progressive Fibrosing Interstitial Lung Disease in 2021, accounting for approximately 10% in 7MM.
Scope of the Report
- The report covers the descriptive overview of Progressive Fibrosing Interstitial Lung Disease, explaining its symptoms, grading, pathophysiology, and various diagnostic approaches.
- The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), Japan.
- The report assesses the disease risk and burden of Progressive Fibrosing Interstitial Lung Disease.
- The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.
Report Highlights
- 11-Year Forecast of Progressive Fibrosing Interstitial Lung Disease
- 7MM Coverage
- Total Diagnosed Prevalent Cases of Progressive Fibrosing Interstitial Lung Disease
Key Questions Answered
- What are the disease risk and burden of Progressive Fibrosing Interstitial Lung Disease?
- What is the historical Progressive Fibrosing Interstitial Lung Disease patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan?
- What would be the forecasted patient pool of Progressive Fibrosing Interstitial Lung Disease at the 7MM level?
- What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Progressive Fibrosing Interstitial Lung Disease?
- Out of the above-mentioned countries, which country would have the highest prevalent population of Progressive Fibrosing Interstitial Lung Disease during the forecast period (2022-2032)?
- At what CAGR the population is expected to grow across the 7MM during the forecast period (2022-2032)?
Reasons to buy
The Progressive Fibrosing Interstitial Lung Disease report will allow the user to -
- Develop business strategies by understanding the trends shaping and driving the 7MM+ Progressive Fibrosing Interstitial Lung Disease epidemiology forecast.
- The Progressive Fibrosing Interstitial Lung Disease epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists.
- The Progressive Fibrosing Interstitial Lung Disease epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the 11-year forecast period using reputable sources.
Key Assessments
- Patient Segmentation
- Disease Risk and Burden
- Risk of Disease by segmentation
- Factors driving growth in a specific patient population
Geographies Covered
- The United States
- EU5 (Germany, France, Italy, Spain, and the United Kingdom)
- Japan
Study Period: 2019-2032
1. Key Insights
2. Report Introduction
3. Progressive Fibrosing Interstitial Lung Diseases (PF-ILD) Epidemiology Overview at a Glance
3.1. Patient Share (%) Distribution of PF-ILD in 2019
3.2. Patient Share (%) Distribution of PF-ILD in 2032
4. Executive Summary of Progressive Fibrosing Interstitial Lung Diseases (PF-ILD)
5. Disease Background and Overview: Progressive Fibrosing Interstitial Lung Disease (PF-ILD)
5.1. Introduction
5.2. Types of ILDs progressing into PF-ILD
5.2.1. IPF
5.2.2. Chronic hypersensitivity pneumonitis (HP)
5.2.3. Idiopathic nonspecific interstitial pneumonia (INSIP)
5.2.4. Unclassifiable idiopathic interstitial pneumonia (unclassifiable IIPs)
5.2.5. Autoimmune interstitial lung diseases (CTD-ILDs)
5.2.6. Rheumatoid arthritis-associated interstitial lung disease (RA-ILD)
5.2.7. SSc-ILD
5.2.8. Connective tissue disease less commonly associated with PF-ILD
5.2.9. Chronic sarcoidosis
5.2.10. Exposure-related ILDs
5.3. Pathogenesis of PF-ILD
5.4. Predictors of Disease Progression
5.5. Diagnosis of Progressive-Fibrosing Interstitial Lung Disease (PF-ILD)
5.6. Diagnostic Algorithm of PF-ILD
6. Epidemiology and Patient Population
6.1. Key Findings
6.2. Methodology of Epidemiology
6.3. Assumptions and Rationale: 7MM
6.3.1. United States
6.3.2. EU5 Countries
6.3.3. Japan
6.4. Total Diagnosed Prevalent Cases of Progressive Fibrosing Interstitial Lung Disease in the 7MM
6.5. Type-specific Diagnosed Prevalent Cases of Interstitial Lung Disease in the 7MM
6.6. The United States
6.6.1. Total Prevalent Cases of ILD in the United States
6.6.2. Total Diagnosed Prevalent Cases of ILD in the United States
6.6.3. Type-specific Diagnosed Prevalent Cases of ILD in the United States
6.6.4. Total Diagnosed Prevalent cases of PF-ILD in the United States
6.7. Major Five European Countries
6.7.1. Total Prevalent Cases of ILD in the EU5
6.7.2. Total Diagnosed Prevalent Cases of ILD in the EU5
6.7.3. Type-specific Diagnosed Prevalent Cases of ILD in the EU5
6.7.4. Total Diagnosed Prevalent cases of PF-ILD in the EU-5
6.8. Japan
6.8.1. Total Prevalent Cases of ILD in Japan
6.8.2. Total Diagnosed Prevalent Cases of ILD in Japan
6.8.3. Type-specific Diagnosed Prevalent Cases of ILD in Japan
6.8.4. Total Diagnosed Prevalent cases of PF-ILD in Japan
7. Patient Journey
8. Key Opinion Leaders' Views
9. Appendix
9.1. Bibliography
9.2. Report Methodology
10. DelveInsight Capabilities
11. Disclaimer
12. About DelveInsight
Table 1: Summary of PF-ILD Epidemiology (2019-2032)
Table 2: Total Diagnosed Prevalent cases of PF-ILD in the 7MM (2019-2032)
Table 3: Type-specific Diagnosed Prevalent Cases of ILD in the 7MM (2019-2032)
Table 4: Total Prevalent Cases of ILD in the US (2019-2032)
Table 5: Total Diagnosed Prevalent Cases of ILD in the US (2019-2032)
Table 6: Type-specific Diagnosed Prevalent Cases of ILD in the US (2019-2032)
Table 7: Total Diagnosed Prevalent Cases of PF-ILD in the US (2019-2032)
Table 8: Total Prevalent Cases of ILD in the EU5 (2019-2032)
Table 9: Total Diagnosed Prevalent Cases of ILD in the EU5 (2019-2032)
Table 10: Type-specific Diagnosed Prevalent Cases of ILD in Germany (2019-2032)
Table 11: Type-specific Diagnosed Prevalent Cases of ILD in France (2019-2032)
Table 12: Type-specific Diagnosed Prevalent Cases of ILD in Italy (2019-2032)
Table 13: Type-specific Diagnosed Prevalent Cases of ILD in Spain (2019-2032)
Table 14: Type-specific Diagnosed Prevalent Cases of ILD in the UK (2019-2032)
Table 15: Type-specific Diagnosed Prevalent Cases of ILD in the EU5 (2019-2032)
Table 16: Total Diagnosed Prevalent Cases of PF-ILD in the EU5 (2019-2032)
Table 17: Total Prevalent Cases of ILD in Japan (2019-2032)
Table 18: Total Diagnosed Prevalent Cases of ILD in Japan (2019-2032)
Table 19: Type-specific Diagnosed Prevalent Cases of ILD in Japan (2019-2032)
Table 20: List of Abbreviations
Figure 1: ILDs with Overlapping Area Shows the Probability of Having a Progressive-Fibrosing Phenotype
Figure 2: Known and Unknowns of PF-ILDs
Figure 3: Types of ILD Most Likely to Have a Progressive-fibrosing Phenotype
Figure 4: Fibrosis of the Alveolus Wall
Figure 5: Types of CTD-ILD
Figure 6: Concepts in the Pathogenesis of RA-ILD
Figure 7: Mechanisms Involved in the Pathogenesis and Progression of Fibrosing Interstitial Lung Diseases
Figure 8: Diagnosis of ILDs that may present a Progressive Phenotype
Figure 9: Total Diagnosed Prevalent Cases of PF-ILD in the 7MM (2019-2032)
Figure 10: Type-specific Diagnosed Prevalent Cases of ILD in the 7MM (2019-2032)
Figure 11: Total Prevalent Cases of ILD in the US (2019-2032)
Figure 12: Total Diagnosed Prevalent Cases of ILD in the US (2019-2032)
Figure 13: Type-specific Diagnosed Prevalent Cases of ILD in the US (2019-2032)
Figure 14: Total Diagnosed Prevalent Cases of PF-ILD in the US (2019-2032)
Figure 15: Total Prevalent Cases of ILD in the EU5 (2019-2032)
Figure 16: Total Diagnosed Prevalent Cases of ILD in the EU5 (2019-2032)
Figure 17: Type-specific Diagnosed Prevalent Cases of ILD in the EU5 (2019-2032)
Figure 18: Total Diagnosed Prevalent Cases of PF-ILD in the EU5 (2019-2032)
Figure 19: Total Prevalent Cases of ILD in Japan (2019-2032)
Figure 20: Total Diagnosed Prevalent Cases of ILD in Japan (2019-2032)
Figure 21: Type-specific Diagnosed Prevalent Cases of ILD in Japan (2019-2032)
Figure 22: Total Diagnosed Prevalent Cases of PF-ILD in Japan (2019-2032)
Figure 23: Patient Journey
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security